“jazz-pharmaceuticals” Archives

in
Entry Author Date Location
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin 10/14/20 Boston
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs 09/28/20 Boston
Now Closer to Clinical Trials, Codiak BioSciences Refiles IPO Plans 09/10/20 Boston
Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup 08/11/20 San Diego
Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More 07/24/20 National
Jazz Pharma Gets FDA Nod for New Drug to Treat Narcolepsy Symptoms 07/22/20 Europe
Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds 06/22/20 Boston
Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More 06/19/20 National
Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug 06/15/20 National
Exosomes Head to Wall Street As Codiak Biosciences Lines Up IPO 04/30/19 Boston
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More 04/19/19 National
Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More 05/04/18 National
Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More 09/01/17 National
Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More 08/29/17 Boston
Bio Roundup: CRISPR Advances, Obamacare Lives, FDA Nods & More 08/04/17 National
BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders 10/20/16 San Francisco
Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes 06/03/16 National
Celator Parlays Leukemia Drug Data into $1.5B Buyout From Jazz Pharma 05/31/16 New York
Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More 05/27/16 National
Arrivo BioVentures Lands $49M to Fuel Hunt for New Drugs 05/26/16 Raleigh Durham
East Coast Biotech Roundup: NY Bio, Synageva, Kadmon & More 05/08/15 New York
“Voice for Everyone”—Life-Sci Women Talk Venture, Pharma Gender Gap 03/04/15 San Francisco
West Coast Biotech Roundup: Tobira, Novartis, NantCell, & More 01/15/15 San Francisco
Prescription Drug Pricing: The Fine Line Between Value and Greed 12/02/14 Boston
How A Kidney Drug Almost Torpedoed Concert Pharma’s IPO 04/25/14 Boston
Tumor Cells’ Weird Appetites for Amino Acids Are Aeglea’s Targets 02/19/14 Texas
East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More 02/14/14 Boston
Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share 02/13/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
Zalicus Awaits Day of Reckoning, Braces For Key Pain Drug Results 11/11/13 Boston
Page 1 of 2 next page »